Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Yamazaki

Showing results (91-100 of 252) with videos related to

Pageof 26
Sort By:
Japanese Journal of Clinical Oncology|December 21, 2010
Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancerToshihiko Doi, Makoto Tahara, Takayuki Yoshino, et al.
Journal of Gastroenterology|November 18, 2008
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancerKoichi Taira, Narikazu Boku, Akira Fukutomi, et al.
Investigational New Drugs|July 28, 2022
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort studySae Ohwada, Akiko Todaka, Hiroshi Nakase, et al.
Cancer Science|June 7, 2018
Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third EditionKentaro Yamazaki, Hiroya Taniguchi, Takayuki Yoshino, et al.
Scientific Reports|October 20, 2023
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS studyMamiko Shiroyama, Shota Fukuoka, Toshiki Masuishi, et al.
Pancreas|April 14, 2011
Risk factors of familial pancreatic cancer in Japan: current smoking and recent onset of diabetesHiroyuki Matsubayashi, Atsuyuki Maeda, Hideyuki Kanemoto, et al.
Japanese Journal of Clinical Oncology|October 8, 2011
S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapyTomoya Yokota, Yusuke Onozawa, Narikazu Boku, et al.
American Journal of Clinical Oncology|October 1, 2015
Risk Analysis of Pneumonitis in Taxane Therapy After Chemoradiotherapy for Patients With Metastatic or Recurrent Esophageal CancerYoshihiro Kishida, Takahiro Tsushima, Masahiro Endo, et al.
Japanese Journal of Clinical Oncology|March 2, 2010
S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failureAkiko Todaka, Akira Fukutomi, Narikazu Boku, et al.
International Journal of Clinical Oncology|May 9, 2008
A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinumKentaro Yamazaki, Shuichi Hironaka, Narikazu Boku, et al.
Pageof 26

Showing results (91-100 of 252) with videos related to

Sort By:
Pageof 26
Japanese Journal of Clinical Oncology|December 21, 2010
Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancerToshihiko Doi, Makoto Tahara, Takayuki Yoshino, et al.
Journal of Gastroenterology|November 18, 2008
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancerKoichi Taira, Narikazu Boku, Akira Fukutomi, et al.
Investigational New Drugs|July 28, 2022
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort studySae Ohwada, Akiko Todaka, Hiroshi Nakase, et al.
Cancer Science|June 7, 2018
Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third EditionKentaro Yamazaki, Hiroya Taniguchi, Takayuki Yoshino, et al.
Scientific Reports|October 20, 2023
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS studyMamiko Shiroyama, Shota Fukuoka, Toshiki Masuishi, et al.
Pancreas|April 14, 2011
Risk factors of familial pancreatic cancer in Japan: current smoking and recent onset of diabetesHiroyuki Matsubayashi, Atsuyuki Maeda, Hideyuki Kanemoto, et al.
Japanese Journal of Clinical Oncology|October 8, 2011
S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapyTomoya Yokota, Yusuke Onozawa, Narikazu Boku, et al.
American Journal of Clinical Oncology|October 1, 2015
Risk Analysis of Pneumonitis in Taxane Therapy After Chemoradiotherapy for Patients With Metastatic or Recurrent Esophageal CancerYoshihiro Kishida, Takahiro Tsushima, Masahiro Endo, et al.
Japanese Journal of Clinical Oncology|March 2, 2010
S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failureAkiko Todaka, Akira Fukutomi, Narikazu Boku, et al.
International Journal of Clinical Oncology|May 9, 2008
A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinumKentaro Yamazaki, Shuichi Hironaka, Narikazu Boku, et al.
Pageof 26